EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer

Weifang Tang, Qilin Zhou iD, Jianjun Liu iD, Shikai Hong

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261470682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 18.08.2026. Verfasst von Weifang Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether the HLX-02 plus pertuzumab offers superior efficacy compared to the HLX-02 plus pyrotinib in the early-stage setting remains unclear, highlighting a critical gap in evidence for optimizing neoadjuvant therapy selection.

Objective

To compare the efficacy and safety of neoadjuvant chemotherapy regimens combining the trastuzumab biosimilar HLX-02 with either pertuzumab or pyrotinib in patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Design

This is a retrospective cohort study.

Methods

This retrospective cohort study enrolled patients with HER2-positive breast cancer who received neoadjuvant therapy at The First Affiliated Hospital of University of Science and Technology of China between October 2021 and July 2024. Participants were divided into two treatment groups: those receiving docetaxel, carboplatin, HLX‑02 plus pertuzumab (TCbHP group), and those receiving docetaxel, carboplatin, HLX‑02 (a trastuzumab biosimilar ) plus pyrotinib (TCbHPy group). To minimize selection bias, propensity score matching (PSM) was applied in a 1:2 ratio before evaluating efficacy and safety. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included safety outcomes, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Results

A total of 101 patients were initially included. After PSM, 55 patients were selected (TCbHP group: n = 36; TCbHPy group: n = 19). The overall pCR rates were comparable between the groups (TCbHP group: 58.3% vs TCbHPy group: 52.6%, p = 0.778). Subgroup analysis showed that amonghormone receptor–positive (HR+) patients, pCR rates were 50.0% in the TCbHP group and 44.4% in the TCbHPy group. For HR negative (HR−) patients, pCR rates were 63.6% and 60.0%, respectively. The overall incidence of adverse events was 80.6% in the TCbHP group and 94.7% in the TCbHPy group. Notably, non-hematologic toxicities differed significantly between the groups, with a markedly higher incidence of diarrhea (grade ⩾3+: 47.3%) observed in the TCbHPy group.

Conclusion

Both HLX‑02‑based neoadjuvant regimens exhibited comparable efficacy in achieving pCR in patients with HER2‑positive breast cancer. These findings indicate that HLX‑02, whether combined with pertuzumab or pyrotinib, represents a viable neoadjuvant strategy.

Schlagwörter

Stichwörter der Autor:innen

HLX-02breast cancerneoadjuvant therapypertuzumabpyrotinibtargeted therapy

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
  • Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Department of Breast Surgery, Anhui Provincial Cancer Hospital, Hefei, China.
  • Graduated School, Wannan Medical University, Wuhu, China.
  • Department of Breast Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230026, China.

ORCID-Profile: Qilin Zhou, Jianjun Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tang, W., Zhou, Q., Liu, J., & Hong, S. (2026). Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261470682

Vancouver

Tang W, Zhou Q, Liu J, Hong S. Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261470682

BibTeX
@article{Tang2026,
  author = {Tang, Weifang and Zhou, Qilin and Liu, Jianjun and Hong, Shikai},
  title = {Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261470682}
}
Kostenlos starten →